NJBIZ2 小时
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
来自MSN3 小时
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
FDA approves first nasal spray treatment for severe depression
The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe ...
6 Things To Know About Stimulant Medications For ADHD
Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD.
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Nebraska Examiner18 小时
Lawmaker proposes new medication abortion requirements, documentation in Nebraska
A pregnant woman seeking a medication abortion would be required to attend an in-person appointments before and after ...
WPIX New York City, NY on MSN22 小时
Nose spray to treat depression? FDA approves first-of-its-kind medicine
Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to Johnson & Johnson.
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...